Included first 300 (75%) patients in GALA-ALD

Identified eligible patients with current or prior alcohol overuse and alcoholic liver fibrosis along the entire spectrum of disease. Eligible patients are recruited from alcohol abuse centres, outpatient liver clinics, emergency rooms and family physicians in Region of Southern Denmark and via national web adverts. Collected informed consent, tissue samples and clinical data for first 300 GALA-ALD patients. After consent a one-day inclusion visit are scheduled. We will perform: (i) liver biopsy, (ii) collection of venous fasting blood, faeces, urine and saliva, (iii) physical examinations including anthropometric data, abdominal ultrasonography, heart rate and blood pressure, (iv) non-invasive assessment of liver fibrosis using transient elastography, real-time shear-wave elastography and serum markers, (v) questionnaires evaluating alcohol use, alcohol dependency, demographic data, medicine use, comorbidity and health-related quality of life.